PPARG and metabolic dysfunction-associated steatotic liver disease: Mutations in genes associated with lipodystrophy, such as the peroxisome proliferator-activated receptor-gamma (PPARγ), lamin A/C (LMNA), and hormone-sensitive lipase genes, are potential therapeutic targets for NAFLD (DiStefano and Gerhard, 2022).